# Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

> **NCT03745586** · PHASE1,PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 18 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Glucocorticoids

## Key facts

- **NCT ID:** NCT03745586
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-03-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745586, "Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03745586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*